Hussman Strategic Advisors Inc. Sells 61,000 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Hussman Strategic Advisors Inc. lowered its stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWDFree Report) by 49.2% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 63,000 shares of the biotechnology company’s stock after selling 61,000 shares during the quarter. Hussman Strategic Advisors Inc.’s holdings in Ironwood Pharmaceuticals were worth $721,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. Signaturefd LLC raised its position in shares of Ironwood Pharmaceuticals by 61.4% in the 4th quarter. Signaturefd LLC now owns 2,160 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 822 shares during the period. Daiwa Securities Group Inc. increased its stake in Ironwood Pharmaceuticals by 331.6% in the fourth quarter. Daiwa Securities Group Inc. now owns 2,473 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,900 shares in the last quarter. Natixis acquired a new stake in Ironwood Pharmaceuticals in the fourth quarter worth $30,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Ironwood Pharmaceuticals by 96.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,997 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 1,961 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its holdings in shares of Ironwood Pharmaceuticals by 41.4% in the 2nd quarter. PNC Financial Services Group Inc. now owns 3,647 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 1,067 shares during the period.

Insider Buying and Selling

In related news, SVP Andrew Davis sold 9,846 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $15.24, for a total value of $150,053.04. Following the sale, the senior vice president now owns 208,324 shares of the company’s stock, valued at approximately $3,174,857.76. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, SVP Andrew Davis sold 9,846 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $15.24, for a total transaction of $150,053.04. Following the completion of the transaction, the senior vice president now directly owns 208,324 shares of the company’s stock, valued at approximately $3,174,857.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Thomas A. Mccourt sold 177,164 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $15.24, for a total transaction of $2,699,979.36. Following the completion of the sale, the chief executive officer now owns 832,774 shares in the company, valued at $12,691,475.76. The disclosure for this sale can be found here. Over the last three months, insiders sold 273,008 shares of company stock worth $4,160,642. 13.10% of the stock is owned by corporate insiders.

Ironwood Pharmaceuticals Price Performance

IRWD opened at $7.91 on Monday. The business’s 50-day moving average price is $10.21 and its two-hundred day moving average price is $10.72. Ironwood Pharmaceuticals, Inc. has a 1 year low of $7.53 and a 1 year high of $15.70.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. StockNews.com downgraded Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, April 6th. Craig Hallum initiated coverage on Ironwood Pharmaceuticals in a research report on Wednesday, January 17th. They set a “buy” rating and a $21.00 price target on the stock. Piper Sandler lifted their price objective on Ironwood Pharmaceuticals from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Finally, Wells Fargo & Company lowered their target price on Ironwood Pharmaceuticals from $20.00 to $14.00 and set an “overweight” rating for the company in a research note on Friday, March 1st. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $19.80.

Read Our Latest Research Report on IRWD

About Ironwood Pharmaceuticals

(Free Report)

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.

See Also

Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWDFree Report).

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.